🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Results from our phase 3 SYMPATICO trial of ibrutinib plus venetoclax in R/R MCL show that the combination improved PFS relative to ibrutinib-placebo (31.9 vs 22.1 mo., HR 0.65, p = 0.005), with a safety profile consistent with its individual drugs. tinyurl.com/SYMPAT

🎉 Out now in Blood Advances 🙌🏽 Our work from Princess Margaret Cancer Centre looking at PTCy in matched sibling donor allogeneic transplantation with an excellent commentary by my good friend Nico Gagelmann 👇🏽 #MedTwitter ashpublications.org/bloodadvances/…

Off-the-shelf CAR-T is here! Our phase 1 trial in Journal of Clinical Oncology shows allogeneic CD19 CAR-T cemacabtagene ansegedleucel (cema-cel) delivers durable remissions in R/R DLBCL: 🔹42% CR rate with median CR duration 23.1 months 🔹No GVHD, ICANS, or severe CRS ascopubs.org/doi/10.1200/JC…

Announcing the inaugural inductees into the Princess Margaret Hall of Fame! 🏆 These eight visionary clinicians have dedicated decades to advancing cancer care. (1/2)

Lenalidomide combined with R-CHOP (R2-CHOP) in the treatment of newly diagnosed double-expressor diffuse large B-cell lymphoma: a prospective phase II clinical trial Blood Cancer Journal nature.com/articles/s4140…

Our Phase 1b study in Haematologica shows that triple combination acalabrutinib, bendamustine, and rituximab (ABR) was effective in patients with treatment-naïve or relapsed/refractory #MCL with a similar toxicity as single-agents. tinyurl.com/23v647bd

Happy Polycomb Day (3/27)! Today we celebrate H3K27me3- Polycomb’s quiet mark of repression, where gene silencing is not neglect, but a deliberate act of identity.

Prizloncabtagene autoleucel: a new CAR T cell for B-NHL ashpublications.org/blood/article/… Anna Sureda

One-size does not fit all: If you ever happen to see a LBCL with excellent chemosensitivity: Auto in those circumstance still reasonable. Fateeha Furqan extends our previous work now to MYC rearranged LBCL @cibmtr #bmtsm onlinelibrary.wiley.com/doi/10.1002/aj…

International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations ashpublications.org/blood/article/…

This #WHD2025, the National Coagulation Centre at St James's Hospital is championing and strengthening access to care for women & girls with bleeding symptoms - ensuring support at every step! Watch our video here 👉stjames.ie/services/hope/…

🚨New Blood Advances issue out now featuring: Hepatosplenic T-cell lymphoma in children and adolescents ow.ly/i2vm50VBIEi

New data from our group! Working with Kholodenko/Rukhlenko groups Systems Biology Ire we used structure-based modelling to find novel non-expected AML drug combos, which we validated in vivo. Huge thanks to Irish Cancer Society for funding Luke Jones Luke Jones biorxiv.org/content/10.110…

🚨We made the list🚨 For the first time ever, St James’s Hospital is one of Ireland’s Top 80 Places to Work 💙 Huge thanks to our incredible team #ProudToWorkHere independent.ie/business/irela…

Excited to share our new paper out today in Molecular Cell! We show that the H3K27M oncohistone rewires cPRC1, creating a unique dependency on CBX4/PCGF4-containing complexes, and also reveal a previously unknown function of CBX4. Highlights below (1/11).

CONGRESS | #ASCO25 | POSTER Pierluigi Porcu of Sidney Kimmel Comprehensive Cancer Center, shared long-term results from the phase 2 TELLAMAK study of lacutamab in heavily pretreated pts with R/R Sezary syndrome (n=63). Long-term follow-up data demonstrated high response rate and long-lasting response:

#ASCO25 #AML #leusm ASCERTAIN-V Trial presented by Dr. Zeidan Amer Zeidan MBBS,MHS ‏عامر زيدان all oral regimen (oral decitabine/cedazuridine plus venetoclax) for AML ineligible to IC. 1. CR/CRh 51.5%, CR/CRi 63% 2. mOS 15.5 months Results comparable to #VIALE_A trial with all oral regimen.

New ICD-10-CM codes for the Duffy phenotype have recently been released. What are the implications for patients and what does this mean for healthcare? Learn more: ow.ly/YGRq50W2Qmp #DuffyNull #Hematology #DANC #ASHEducation

#mmsm Journal of Clinical Oncology New definition of high risk multiple myeloma by IMWG ➡️ascopubs.org/doi/10.1200/JC… Summary 👇

Big news: Mosun-Pola is superior to chemotherapy for patients with aggressive lymphoma. At International Conference on Malignant Lymphoma, I was honored to present—on behalf of an incredible team of global coauthors—the SUNMO trial: ➡️ First positive Phase III trial in this space without conventional chemotherapy